SEQIRUS for SEQIRUS
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2023 | $190,000 | Replaced |
| 2nd Quarter - Amendment | Oct 20, 2023 | $220,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY2024 Appropriations and supplemental appropriations; H.R. 9476 Protecting America from Seasonal and Pandemic Influenza Act of 2022; Pandemic and All-Hazards Preparedness Reauthorization; Department of Defense and Veterans Administration acquisition of influenza vaccine
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Health Issues HCR
Issues related to seasonal and pandemic influenza preparedness.
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.